Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease.
NAFLD
PRO-C3
PRO-C6
insulin resistance
irisin
liver fibrogenesis
liver fibrosis
non-invasive biomarkers
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
27 Jan 2022
27 Jan 2022
Historique:
received:
31
12
2021
revised:
18
01
2022
accepted:
26
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Insulin resistance plays a relevant role in the onset of non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and fibrosis. Irisin is an exercise-induced myokine involved in the regulation of energy homeostasis and glucose metabolism. Additionally, pre-clinical models have shown a potential role of irisin in the pathogenesis of NAFLD. The aim of this study is to explore the association between irisin, histological features and biomarkers of liver fibrogenesis in non-diabetic, non-obese, biopsy-proven NAFLD individuals. Forty-one patients with histological evidence of NAFLD were included. Circulating irisin and direct markers of fibrogenesis N-terminal type III collagen propeptide (PRO-C3) and type VI collagen cleavage product (PRO-C6) were measured by ELISA. Median age of the cohort was 45 years (41-51) and 80.4% were male. Significant fibrosis (stage ≥ 2) was present in 36.6% of cases. Circulating irisin, PRO-C3 and PRO-C6 levels were significantly higher in subjects with fibrosis stage ≥ 2 when compared to those with fibrosis stage < 2 (5.96 ng/mL (95% CI = 4.42-9.19) vs. 2.42 ng/mL (95% CI = 1.73-5.95), Increased circulating irisin levels may identify a more aggressive phenotype of liver disease with increased fibrogenesis and more severe liver damage.
Sections du résumé
BACKGROUND
BACKGROUND
Insulin resistance plays a relevant role in the onset of non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and fibrosis. Irisin is an exercise-induced myokine involved in the regulation of energy homeostasis and glucose metabolism. Additionally, pre-clinical models have shown a potential role of irisin in the pathogenesis of NAFLD. The aim of this study is to explore the association between irisin, histological features and biomarkers of liver fibrogenesis in non-diabetic, non-obese, biopsy-proven NAFLD individuals.
METHODS
METHODS
Forty-one patients with histological evidence of NAFLD were included. Circulating irisin and direct markers of fibrogenesis N-terminal type III collagen propeptide (PRO-C3) and type VI collagen cleavage product (PRO-C6) were measured by ELISA.
RESULTS
RESULTS
Median age of the cohort was 45 years (41-51) and 80.4% were male. Significant fibrosis (stage ≥ 2) was present in 36.6% of cases. Circulating irisin, PRO-C3 and PRO-C6 levels were significantly higher in subjects with fibrosis stage ≥ 2 when compared to those with fibrosis stage < 2 (5.96 ng/mL (95% CI = 4.42-9.19) vs. 2.42 ng/mL (95% CI = 1.73-5.95),
CONCLUSIONS
CONCLUSIONS
Increased circulating irisin levels may identify a more aggressive phenotype of liver disease with increased fibrogenesis and more severe liver damage.
Identifiants
pubmed: 35160087
pii: jcm11030635
doi: 10.3390/jcm11030635
pmc: PMC8837035
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Dipartimenti di Eccellenza 2018-2022
ID : D15D18000410001
Organisme : Horizon 2020-EU.3.1.1
ID : 634413
Références
Free Radic Biol Med. 2014 Oct;75 Suppl 1:S16
pubmed: 26461295
Int J Obes (Lond). 2015 Jan;39(1):156-61
pubmed: 24916788
Gastroenterol Res Pract. 2020 Nov 7;2020:8818191
pubmed: 33224193
Diabetol Metab Syndr. 2014 Dec 05;6(1):133
pubmed: 25530809
J Clin Endocrinol Metab. 2013 Apr;98(4):E769-78
pubmed: 23436919
J Hepatol. 2019 Mar;70(3):494-500
pubmed: 30389552
Hepatology. 2019 Jul;70(1):127-141
pubmed: 30859582
Metabolites. 2021 Mar 08;11(3):
pubmed: 33800465
J Clin Endocrinol Metab. 2017 Aug 1;102(8):2660-2669
pubmed: 28472477
J Clin Med. 2020 Sep 29;9(10):
pubmed: 33003490
J Clin Endocrinol Metab. 2014 Aug;99(8):2778-85
pubmed: 24780049
J Hepatol. 2017 Dec;67(6):1265-1273
pubmed: 28803953
Nature. 2012 Jan 11;481(7382):463-8
pubmed: 22237023
J Hepatol. 2013 Sep;59(3):557-62
pubmed: 23665283
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Sci Rep. 2020 Sep 30;10(1):16093
pubmed: 32999391
Mol Endocrinol. 2016 May;30(5):533-42
pubmed: 27007446
Geriatr Gerontol Int. 2017 Nov;17(11):2266-2273
pubmed: 28394089
Diabetes Care. 2019 Jul;42(7):1348-1351
pubmed: 31221701
Metabolism. 2016 Jun;65(6):825-34
pubmed: 27173461
EBioMedicine. 2016 Apr;6:139-148
pubmed: 27211556
Int J Obes (Lond). 2014 Dec;38(12):1538-44
pubmed: 24614098
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Clin Sci (Lond). 2015 Nov;129(10):839-50
pubmed: 26201094
J Physiol. 2014 Mar 1;592(5):1091-107
pubmed: 24297848
PLoS One. 2015 Apr 21;10(4):e0124100
pubmed: 25897751